Boston, MA – Elucid, a Boston-based healthcare technology company focused on improving care for cardiovascular disease (CVD), has raised $8 million in Series A financing. Elucid will use the funding to continue work on its AI-based software designed to detect signs of CVD.
“This latest round of financing will enable us to continue advancing our unique technology for non-invasive estimation of cardiovascular event risk, myocardial ischemia and therapeutic response,” Blake Richards, CEO of Elucid, said in a statement. “This funding is validation of the market need for technology like Elucid’s to enable more accurate diagnosis of cardiovascular disease and patient-specific treatment decisions.” READ MORE